KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Accumulated Expenses (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Other Accumulated Expenses readings, the most recent being $1.1 billion for Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses rose 15.25% to $1.1 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 15.25% increase, with the full-year FY2025 number at $1.2 billion, up 15.88% from a year prior.
  • Other Accumulated Expenses hit $1.1 billion in Q1 2026 for Teva Pharmaceutical Industries, down from $1.2 billion in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $1.2 billion in Q3 2024 to a low of $900.0 million in Q1 2022.
  • Median Other Accumulated Expenses over the past 5 years was $1.0 billion (2023), compared with a mean of $1.0 billion.
  • Biggest five-year swings in Other Accumulated Expenses: increased 22.75% in 2024 and later fell 21.07% in 2025.
  • Teva Pharmaceutical Industries' Other Accumulated Expenses stood at $1.0 billion in 2022, then grew by 3.88% to $1.0 billion in 2023, then dropped by 2.3% to $1.0 billion in 2024, then grew by 15.88% to $1.2 billion in 2025, then decreased by 6.01% to $1.1 billion in 2026.
  • The last three reported values for Other Accumulated Expenses were $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.1 billion (Q3 2025) per Business Quant data.